Aptevo Therapeutics Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Aptevo Therapeutics Inc. (APVO) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$6.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-14
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$6.36M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$6.70M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$6.20M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$6.41M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $7.01M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$29.41M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$30.92M.
- Aptevo Therapeutics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was -$43.06M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.36M 10-Q · filed 2026-08-14 | -$13.05M 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | -$6.70M 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | -$25.97M DEF 14A · filed 2026-07-31 | ||||||
| 2025-06-30 | -$6.20M 10-Q · filed 2026-08-14 | -$12.61M 10-Q · filed 2026-08-14 | -$18.92M derived: sum of 3 quarters · filed 2026-08-14 | -$24.02M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$6.41M 10-Q · filed 2026-05-13 | -$12.72M derived: sum of 2 quarters · filed 2026-07-31 | -$17.82M derived: sum of 3 quarters · filed 2026-07-31 | -$23.70M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2024-12-31 | -$6.31M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-07-31 | -$11.41M derived: sum of 2 quarters · filed 2026-07-31 | -$17.30M derived: sum of 3 quarters · filed 2026-07-31 | -$24.13M DEF 14A · filed 2026-07-31 | |||
| 2024-09-30 | -$5.10M 10-Q · filed 2024-11-07 | -$10.98M derived: sum of 2 quarters · filed 2024-11-07 | -$17.82M 10-Q · filed 2024-11-07 | -$22.77M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2024-06-30 | -$5.88M 10-Q · filed 2024-08-08 | -$12.72M 10-Q · filed 2024-08-08 | -$17.67M derived: sum of 3 quarters · filed 2026-07-31 | -$24.01M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2024-03-31 | -$6.83M 10-Q · filed 2024-05-08 | -$11.79M derived: sum of 2 quarters · filed 2026-07-31 | -$18.13M derived: sum of 3 quarters · filed 2026-07-31 | -$26.07M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2023-12-31 | -$4.96M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-07-31 | -$11.29M derived: sum of 2 quarters · filed 2026-07-31 | -$19.24M derived: sum of 3 quarters · filed 2026-07-31 | -$17.41M DEF 14A · filed 2026-07-31 | -$18.65M 10-K · filed 2024-03-05 | ||
| 2023-09-30 | -$6.33M 10-Q · filed 2024-11-07 | -$14.28M derived: sum of 2 quarters · filed 2024-11-07 | -$12.45M 10-Q · filed 2024-11-07 | -$17.62M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$7.95M 10-Q · filed 2024-08-08 | -$6.12M 10-Q · filed 2024-08-08 | -$11.28M derived: sum of 3 quarters · filed 2024-08-08 | -$19.09M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-08 | -$3.34M derived: sum of 2 quarters · filed 2024-05-08 | -$11.14M derived: sum of 3 quarters · filed 2024-05-08 | $16.72M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$12.97M derived: sum of 2 quarters · filed 2024-03-05 | $14.89M derived: sum of 3 quarters · filed 2024-03-05 | $7.01M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$7.81M 10-Q · filed 2023-11-14 | $20.05M derived: sum of 2 quarters · filed 2023-11-14 | $12.18M 10-Q · filed 2023-11-14 | $5.58M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $27.86M 10-Q · filed 2023-08-10 | $19.99M 10-Q · filed 2023-08-10 | $13.39M derived: sum of 3 quarters · filed 2023-08-10 | $6.31M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$7.88M 10-Q · filed 2023-05-11 | -$14.47M derived: sum of 2 quarters · filed 2023-05-11 | -$21.55M derived: sum of 3 quarters · filed 2023-05-11 | -$29.61M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$13.67M derived: sum of 2 quarters · filed 2023-03-30 | -$21.74M derived: sum of 3 quarters · filed 2023-03-30 | -$29.41M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$7.08M 10-Q · filed 2022-11-10 | -$15.14M derived: sum of 2 quarters · filed 2022-11-10 | -$22.81M 10-Q · filed 2022-11-10 | -$29.98M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$8.06M 10-Q · filed 2022-08-11 | -$15.73M 10-Q · filed 2022-08-11 | -$22.91M derived: sum of 3 quarters · filed 2022-08-11 | -$29.85M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | -$7.67M 10-Q · filed 2022-05-12 | -$14.84M derived: sum of 2 quarters · filed 2022-05-12 | -$21.79M derived: sum of 3 quarters · filed 2022-05-12 | -$28.59M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | -$7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$14.12M derived: sum of 2 quarters · filed 2022-03-24 | -$20.92M derived: sum of 3 quarters · filed 2022-03-24 | -$30.92M 10-K · filed 2022-03-24 | |||
| 2020-09-30 | -$6.95M 10-Q · filed 2021-11-12 | -$13.75M derived: sum of 2 quarters · filed 2021-11-12 | -$23.75M 10-Q · filed 2021-11-12 | -$33.15M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | -$6.80M 10-Q · filed 2021-08-12 | -$16.80M 10-Q · filed 2021-08-12 | -$26.20M derived: sum of 3 quarters · filed 2021-08-12 | -$37.29M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$10.00M 10-Q · filed 2021-05-11 | -$19.40M derived: sum of 2 quarters · filed 2021-05-11 | -$30.48M derived: sum of 3 quarters · filed 2021-05-11 | -$41.32M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$20.48M derived: sum of 2 quarters · filed 2021-03-31 | -$31.32M derived: sum of 3 quarters · filed 2021-03-31 | -$43.06M 10-K · filed 2021-03-31 | -$44.70M 10-K · filed 2020-03-25 | ||
| 2019-09-30 | -$11.09M 10-Q · filed 2020-11-10 | -$10.18M 10-Q · filed 2019-11-07 | -$21.93M derived: sum of 2 quarters · filed 2020-11-10 | -$33.67M 10-Q · filed 2020-11-10 | -$35.52M 10-Q · filed 2019-11-07 | -$47.79M derived: sum of 4 quarters · filed 2020-11-10 | |
| 2019-06-30 | -$10.84M 10-Q · filed 2020-08-14 | -$22.58M 10-Q · filed 2020-08-14 | -$36.71M derived: sum of 3 quarters · filed 2020-08-14 | -$49.27M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | -$11.74M 10-Q · filed 2020-05-13 | -$25.87M derived: sum of 2 quarters · filed 2020-05-13 | -$38.43M derived: sum of 3 quarters · filed 2020-05-13 | -$51.59M derived: sum of 4 quarters · filed 2020-05-13 | |||
| 2018-12-31 | -$14.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$26.69M derived: sum of 2 quarters · filed 2020-03-25 | -$39.84M derived: sum of 3 quarters · filed 2020-03-25 | -$53.69M 10-K · filed 2020-03-25 | |||
| 2018-09-30 | -$12.56M 10-Q · filed 2019-11-07 | -$12.60M 10-Q · filed 2018-11-14 | -$25.72M derived: sum of 2 quarters · filed 2019-11-07 | -$39.56M 10-Q · filed 2019-11-07 | -$39.66M 10-Q · filed 2018-11-14 | -$49.32M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | -$13.15M 10-Q · filed 2018-08-09 | -$27.06M 10-Q · filed 2018-08-09 | -$36.76M derived: sum of 3 quarters · filed 2019-03-18 | -$33.77M derived: sum of 4 quarters · filed 2019-03-18 | |||
| 2018-03-31 | -$13.91M 10-Q · filed 2018-05-10 | -$23.60M derived: sum of 2 quarters · filed 2019-03-18 | -$20.62M derived: sum of 3 quarters · filed 2019-03-18 | -$34.79M derived: sum of 4 quarters · filed 2019-03-18 | |||
| 2017-12-31 | -$9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$6.71M derived: sum of 2 quarters · filed 2019-03-18 | -$20.88M derived: sum of 3 quarters · filed 2019-03-18 | -$32.59M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $2.98M 10-Q · filed 2018-11-14 | -$11.18M derived: sum of 2 quarters · filed 2018-11-14 | -$22.90M 10-Q · filed 2018-11-14 | -$39.05M derived: sum of 4 quarters · filed 2018-11-14 | |||
| 2017-06-30 | -$14.17M 10-Q · filed 2018-08-09 | -$25.88M 10-Q · filed 2018-08-09 | -$42.04M derived: sum of 3 quarters · filed 2018-08-09 | -$115.45M derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | -$11.71M 10-Q · filed 2018-05-10 | -$27.87M derived: sum of 2 quarters · filed 2018-05-10 | -$101.28M derived: sum of 3 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | -$16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$89.57M derived: sum of 2 quarters · filed 2018-03-13 | -$119.89M 10-K · filed 2018-03-13 | ||||
| 2016-09-30 | -$73.41M 10-Q · filed 2017-11-13 | -$103.73M 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |